Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Verrica Pharmaceuticals (VRCA) Accumulated Depreciation & Amortization (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Accumulated Depreciation & Amortization data on record, last reported at $1.0 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 16.53% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 16.53%, while the annual FY2025 figure was $1.0 million, 16.53% down from the prior year.
  • Accumulated Depreciation & Amortization reached $1.0 million in Q4 2025 per VRCA's latest filing, up from $1.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.3 million in Q4 2024 and bottomed at $138000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $858600.0, with a median of $1.0 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 175.2% in 2022, then decreased 16.53% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $254000.0 in 2021, then soared by 175.2% to $699000.0 in 2022, then soared by 67.95% to $1.2 million in 2023, then grew by 7.16% to $1.3 million in 2024, then fell by 16.53% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $1.0 million in Q4 2025, $1.0 million in Q3 2025, and $1.1 million in Q2 2025.